2 Result: Arcellx
Arcellx's IND Clinical Hold and Rhythm Pharma's Breakthrough: Weight Loss in HyOb Patients
June 20th, 2023
Arcellx, Inc. (Nasdaq: ACLX) said that its CART-ddBCMA investigational new drug (IND) for the treatment of relapsed or refractory multiple myeloma (rrMM) has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The cl. Read more
Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
May 18th, 2023
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance. Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price t. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Global Scam Networks and the Corporate Infrastructure That Enables Them
November 06th, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
November 05th, 2026New Details Emerge in Amazon Ads Auction-Rigging Case
November 05th, 2026November 02nd, 2026
Member Login